This Subscription Agreement (the "Agreement") is entered into as of the date indicated on the signature page between:
CAGE Chemical Inc., a company duly incorporated under the Business Corporations Act (British Columbia) (Registration No. BC1583257), with its registered address at 11-3737 Pender Street, Burnaby, British Columbia, V5C 2L2, Canada (the "Company"); and
The investor whose name, address and details appear on the signature page of this Agreement (the "Subscriber" or "Investor").
RECITALS
WHEREAS the Company wishes to raise capital from accredited investors pursuant to the accredited investor exemption set out in section 2.3 of National Instrument 45-106 — Prospectus Exemptions ("NI 45-106"); and
WHEREAS the Subscriber desires to subscribe for and purchase from the Company a Simple Agreement for Future Equity ("SAFE") on the terms and conditions set out in this Agreement and the SAFE instrument attached hereto as Schedule A;
NOW THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
ARTICLE 1 — SUBSCRIPTION
1.1 Subscription. Subject to the terms and conditions of this Agreement, the Subscriber hereby irrevocably subscribes for and agrees to purchase from the Company the SAFE in the amount of CAD$ (the "Purchase Amount").
1.2 SAFE Terms. The SAFE is issued on the terms and conditions set out in the SAFE instrument attached as Schedule A, which is incorporated herein by reference and forms part of this Agreement. The Post-Money Valuation Cap for this SAFE is CAD$12,000,000.
1.3 Payment. The Subscriber agrees to pay the Purchase Amount to the Company by wire transfer in immediately available Canadian funds, to the following account, within five (5) business days of executing this Agreement:
1.4 Closing. The subscription shall be accepted, and the SAFE shall be deemed issued, upon the Company countersigning this Agreement and delivering a countersigned copy to the Subscriber. The Company reserves the right to reject any subscription in its sole and absolute discretion.
1.5 Minimum Investment. The minimum Purchase Amount under this Agreement is CAD$10,000 per Subscriber.
ARTICLE 2 — REPRESENTATIONS AND WARRANTIES OF THE SUBSCRIBER
The Subscriber represents, warrants and covenants to the Company as follows, as of the date of this Agreement and as of the date of each closing, and acknowledges that the Company is relying upon such representations and warranties:
2.1 Accredited Investor Status. The Subscriber is purchasing the SAFE as principal and qualifies as an "accredited investor" within the meaning of NI 45-106, and specifically meets at least one of the following criteria (initial all that apply):
| Criterion (NI 45-106 s.1.1) | Initial |
|---|---|
| Annual net income before taxes exceeded CAD$200,000 in each of the 2 most recent calendar years, with reasonable expectation of the same in the current year. | |
| Annual net income before taxes combined with spouse exceeded CAD$300,000 in each of the 2 most recent calendar years, with reasonable expectation of the same in the current year. | |
| Alone or with spouse, owns more than CAD$1,000,000 in financial assets (cash and securities) net of related debt. | |
| Alone or with spouse, has net assets (total assets less total debt) exceeding CAD$5,000,000. |
2.2 Risk Acknowledgement. The Subscriber has completed and signed the Form 45-106F9 (Risk Acknowledgement for Individual Accredited Investors) attached hereto as Schedule B, or if the Subscriber is not an individual, the equivalent risk acknowledgement applicable to its category. The Subscriber acknowledges the following:
- The Subscriber may lose its entire investment of CAD$ ;
- There is no market for the SAFE or the underlying shares, and the Subscriber may not be able to sell or transfer this investment;
- The Company is an early-stage private company with no current revenues and a high degree of business and technological risk;
- The investment is illiquid and may remain so for many years or indefinitely;
- The Subscriber is not relying on any representation by the Company other than as expressly set out in this Agreement.
2.3 Own Account. The Subscriber is purchasing the SAFE for its own account, as principal, for investment purposes only, and not for the benefit of any other person and not with a view to resale or distribution.
2.4 Sophistication. The Subscriber has such knowledge, skill and experience in business and financial matters that it is capable of evaluating the merits and risks of this investment, has reviewed the Company's materials available at cageinnovations.com, and has had the opportunity to ask questions of and receive information from the Company.
2.5 Independent Advice. The Subscriber has been advised to, and has had the opportunity to, consult its own legal, tax and financial advisors in connection with this investment, and has done so to the extent it considers appropriate. The Subscriber is not relying on the Company or any of its representatives for legal, tax or financial advice.
2.6 No Registration. The Subscriber understands and acknowledges that: (i) the SAFE has not been qualified by a prospectus under applicable Canadian securities laws; (ii) there are restrictions on the Subscriber's ability to resell the SAFE and any shares issuable on conversion; and (iii) the Subscriber must hold the SAFE for at least 4 months and one day from the date of issuance unless an exemption from such hold period is available under applicable securities law.
2.7 Regulatory Disclosure Consent. The Subscriber consents to the disclosure of its name, address, telephone number, email address, and investment amount to the British Columbia Securities Commission and any other applicable securities regulator, as required by law, including pursuant to the filing of a report of exempt distribution under NI 45-106.
2.8 Legal Authority. The Subscriber has full legal capacity, power and authority to execute, deliver and perform this Agreement. This Agreement constitutes a legal, valid and binding obligation of the Subscriber, enforceable in accordance with its terms.
2.9 Residency. The Subscriber is a resident of, or its head office is located in, the province, territory or country indicated in its address on the signature page of this Agreement.
2.10 No US Resident (if applicable). If the Subscriber is a resident of the United States or a "U.S. person" as defined under Regulation S of the United States Securities Act of 1933, as amended, the Subscriber represents that it is an "accredited investor" as defined in Rule 501(a) of Regulation D, and acknowledges that the SAFE has not been registered under the U.S. Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption.
ARTICLE 3 — REPRESENTATIONS AND WARRANTIES OF THE COMPANY
3.1 Incorporation. The Company is duly incorporated and validly existing under the Business Corporations Act (British Columbia) and has the corporate power and authority to own its assets and carry on its business as currently conducted.
3.2 Authorization. The execution, delivery and performance of this Agreement and the SAFE have been duly authorized by all necessary corporate action of the Company. This Agreement and the SAFE each constitute a legal, valid and binding obligation of the Company, enforceable in accordance with their respective terms.
3.3 No Conflict. The execution and performance of this Agreement and the SAFE do not violate the Company's notice of articles or articles, or any material agreement to which the Company is a party.
3.4 Private Issuer. The Company is a private issuer as defined under applicable Canadian securities legislation and is not a reporting issuer in any province or territory of Canada.
3.5 Disclosure. The Company has provided or made available to the Subscriber all material information regarding the business, operations and prospects of the Company that the Subscriber has reasonably requested, to the extent available. The Company's research platform at cageinnovations.com provides open-science information about the Company's research programs.
3.6 Compliance. The Company will file a report of exempt distribution with the British Columbia Securities Commission (Form 45-106F6) within 10 days of the first closing of this offering, as required under NI 45-106.
ARTICLE 4 — GENERAL PROVISIONS
4.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. Each party hereby submits to the non-exclusive jurisdiction of the courts of British Columbia for the resolution of any disputes arising under this Agreement.
4.2 Entire Agreement. This Agreement, together with the SAFE (Schedule A) and the Risk Acknowledgement (Schedule B), constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, warranties, agreements and undertakings.
4.3 Amendments. This Agreement may not be amended or modified except by a written instrument signed by both parties.
4.4 Severability. If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall continue in full force and effect.
4.5 Currency. All references to "$" or "CAD$" in this Agreement refer to the lawful currency of Canada.
4.6 Counterparts. This Agreement may be executed in counterparts and by electronic signature, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Electronic signatures shall be deemed valid and binding to the same extent as original signatures.
4.7 Retention. The Company shall retain executed copies of this Agreement, the SAFE and the Risk Acknowledgement for a period of not less than 8 years from the date of the distribution, as required under NI 45-106.
4.8 No Finder's Fee. No finder's fee, commission or other compensation is payable by the Company in connection with this subscription.
IN WITNESS WHEREOF, the parties have executed this Subscription Agreement as of the date written below.
Schedule A: SAFE Instrument (Simple Agreement for Future Equity — Post-Money Valuation Cap CAD$12,000,000). See cageinnovations.com/invest/docs/safe or the attached instrument.
Schedule B: Form 45-106F9 — Risk Acknowledgement for Individual Accredited Investors. See cageinnovations.com/invest/docs/risk or the attached form.
This document is intended for use in British Columbia under the accredited investor prospectus exemption (NI 45-106, s.2.3). This document has been prepared as a starting point for legal review and is not a substitute for advice from a lawyer licensed in Canada. CAGE Chemical Inc. recommends that all parties obtain independent legal advice before signing.